Presurgical octreotide treatment in acromegaly

Metabolism

Volumn 41, Issue 9 SUPPL. 2, 1992, Pages 51-58

  Stevenaert, A ^a,b,c   Harris, A G ^a,b,c   Kovacs, K ^a,b,c   Beckers, A ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; LONG ACTING DRUG; LUTEINIZING HORMONE; OCTREOTIDE; PROLACTIN; PROTIRELIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; INTRAVENOUS DRUG ADMINISTRATION; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SOMATIC CELL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; FEMALE; GROWTH HORMONE; HUMAN; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGE; OCTREOTIDE; PITUITARY NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0026668651     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/0026-0495(92)90031-5     Document Type: Article

References (53)

1. Resultats a moyen et long terme de l'adenomectomie selective. Elements de pronostic
2. Surgical treatment of growth hormone-secreting micro-adenomas
3. Transsphenoidal surgery for acromegaly—Long-term results in 100 patients
4. Acromegalie-gigantisme. Traitement chirurgical par exerese transsphenoidale de l'adenome hypophysaire
5. Surgical treatment of acromegaly
6. The results of transsphenoidal surgery in specific clinical entities
7. Longterm surgical results in acromegaly. Does the immediate postoperative growth hormone level predict the outcome?
8. Treatment of acromegaly by transsphenoidal operation, 90-yttrium implantation and bromocriptine: Results in 230 patients
9. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients
10. Acromegaly: Biochemical assessment of cure after long-term follow-up of transsphenoidal selective adenomectomy
11. Multicenter surgical results in acromegaly
12. Growth hormone release inhibiting hormone in acromegaly
13. Effect of somatostatin in patients with acromegaly
14. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
15. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995
16. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995
17. ® (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the International Multicentre Acromegaly Study Group
18. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate
19. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995)
20. Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: A comparison with bromocriptine
21. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995
22. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: Endocrine and clinical observations
23. ® in various groups of acromegalic patients
24. Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly
25. Thyrotropin-secreting pituitary adenomas: Report of seven cases
26. Effect of treatment with octreotide on the morphology of growth hormone-secreting pituitary adenomas: Study of 24 cases
27. Pituitary microadenomas: Diagnosis with two and three-dimensional MR imaging at 1.5 T before and after injection of Gadolinium
28. Acromegaly, multinodular goiter and silent polyostotic fibrous dysplasia. A variant of the McCune-Albright syndrome
29. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly
30. Acromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor: Successful treatment with long-acting somatostatin analogue SMS 201-995
31. Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumor secreting growth hormone-relcasing factor
32. ®
33. Dose-response study and long-term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly
34. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety
35. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly
36. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients
37. Continuous infusion of octreotide in acromegaly
38. ® in acromegalic patients
39. Long-term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly
40. Continuous chronic intravenous application of SMS 201-995 via an implantable pump in therapy-resistant acromegaly
41. Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump
42. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
43. Somatostatin analog treatment of acromegaly: New aspects
44. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide
45. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients
46. Size changes of a growth hormone- and prolactin-producing adenoma during and after Sandostatin treatment
47. Effects of bromocriptine on prolactinoma morphology
48. Tumors of the pituitary gland
49. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma
50. Preoperative treatment of acromegaly with SMS 201-995: Surgical and pathological observations
51. Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study
52. Hypothalamic hormonal regulation of human growth hormone gene expression in somatotroph adenoma cell cultures
53. Pathology of invasive pituitary tumors with special reference to functional classification